Current position

Fidelity Investments’s Bristol-Myers Squibb Co (BMY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

FMR LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares98.61MHighest verified quarter-end share count
Quarters reported38Verified quarters with shares above zero
What happened?

FMR LLC first reported Bristol-Myers Squibb Co in Q3 2016. The reported position was increased and reduced across later filings. FMR LLC currently reports 16.29M shares. The latest verified filing showed: Bought 52.7% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 52.7% more+5.62M shares · 16.29M shares reported after the change
Filing context

Quarter-end price $57.62

Q3 2025
Sold 36.5% of the position−5.93M shares · 10.30M shares remained
Filing context

Quarter-end price $45.10

Q2 2025
Sold 24.9% of the position−5.39M shares · 16.23M shares remained
Filing context

Quarter-end price $46.29

Q1 2025
Sold 30.5% of the position−9.49M shares · 21.62M shares remained
Filing context

Quarter-end price $60.99

Q4 2024
Sold 30.8% of the position−13.83M shares · 31.11M shares remained
Filing context

Quarter-end price $56.56

Q3 2024
Bought 10.5% more+4.28M shares · 44.94M shares reported after the change
Filing context

Quarter-end price $51.74

Portfolio importance

How important is Bristol-Myers Squibb Co in FMR LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#336of 5572 reported positions
Peak portfolio weight0.6%Q2 2022
Best historical rank#21Q2 2022
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$63.602026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$57.62Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

Coverage is bounded to Fidelity’s top reported positions and material events rather than every security in each Form 13F. The consolidated FMR LLC filing includes multiple Fidelity investment managers. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.